COVID-19 Clinical Trials and Expanded Access

The purpose of this double-blind, randomized, controlled study is to assess safety,reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels,administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age andabove.

The aim of this study is to analyze the impact of video dance class and unsupervisedphysical activity on clinical-functional parameters, self-isolation and non-motorssymptoms in people with Parkinson's disease during the Covid-19 pandemic.

This study aims to evaluate the impact of the COVID-19 pandemic and its measures onlifestyle in Dutch children between 4 - 18 years.

Antioxidants, and particularly polyphenols, have shown protection in respiratorypathologies, which is related to the decrease in the severity of the clinical picture andsuppression of inflammation. This suppression of inflammation may be related to theinhibition of NF-kB polyphenols, where its activation is related to the stimulation of150 stimuli including cytokines (IL-1β, IL-6, THF-α, GM-CSF, MCP-1), TLRs, among others.There may be other additional mechanisms that can help control virus-induced respiratorypathologies, among which are the regulation of reactive oxygen species (ROS) associatedwith tissue destruction caused by the virus and a selective antiviral action can bereported. direct.The standardized P2Et extract obtained from C. spinosa, by the Immunobiology Group of thePontificia Universidad Javeriana, is highly antioxidant, decreases lipid peroxidation andtissue damage and induces complete autophagy in stressed or tumor cells. The induction ofa full autophagic flow could inhibit the replication of beta-coronaviruses likeSARS-CoV-2. Furthermore, P2Et can decrease the factors involved in tissue damage byreducing IL-6 and decrease ILC2 cells of the lung in animals with lung metastases(unpublished data).These antecedents suggest that the supplementation of patients with COVID-19 with theextract P2Et, could improve their general condition and decrease the inflammatorymediators and the viral load.

The current project is a prospective, multicentric cohort study aiming at amultidisciplinary assessment (pulmonary, cardiometabolic, sleep and mental health) of theconsequences of infection by SARS-CoV-2, 3 months after the diagnosis in order to bettercharacterize these complications. 400 patients with a positive diagnosis of SARS-CoV-2will be included in the study 3 months after their diagnosis: They will be followed at 6months, 1 year, 3 years, and 5 years, as function of their after-effects discovered at 3months and their evolution.

The Açaí trial will be testing if the açaí berry extract, a safe natural product withanti-inflammatory properties, can be used as a treatment option in adult patients withCOVID-19 in the community.

In the United Kingdom, there are currently 138,000 confirmed patients with coronavirus,causing 18,738 deaths. Whilst the disease may be mild in the majority of patients, asignificant proportion of patients require intensive care therapy and a ventilator due tolung injury. In addition to lung injury/failure (acute respiratory distress syndrome(ARDS)), around 50% of patients admitted to intensive care develop acute kidney injury(AKI) (requiring advanced support via haemofiltration) and multi-organ failure.It is unclear why patients suffering from COVID-19 develop such severe lung injury(requiring life support or ventilation) or indeed why patients develop other organdysfunction such as kidney injury. The investigators hypothesis that this may due to anover-reaction of the immune system particularly in the lungs. This then results in therelease of various mediators and biological messengers which can be pushed into the bloodbloodstream (exacerbated by positive pressure generated by the ventilator). Thesemediators then travel, via the blood, to other organs such as the kidney where they causeinflammation and injury of cells, resulting in organ failure.The investigators would like to apply their well-established laboratory methods tofurther the scientific community's knowledge of this severe and deadly viral conditionand we hope that this would lead to the development of medication that would treat thisdeadly virus.

This study collects blood samples, medical information, and medical images from patientswho are being treated for cancer and have a positive test for SARS CoV-2, the newcoronavirus that causes the disease called COVID-19. Collecting blood samples, medicalinformation, and medical images may help researchers determine how COVID-19 affects theoutcomes of patients undergoing cancer treatment and how having cancer affects COVID-19.

The Coronavirus disease 2019 (COVID-19) had its outbreak in late 2019 in China and isconsidered a biological disaster. With medical organizations and staff on the frontline,the investigators should conduct assessments, for the different tiers of medical staff,patients, and community residents, on the short- term psychological and mentaldisabilities or danger factors that they might have faced. As such, the investigators candesign and establish a set of evaluative indicators of the risks of biological disasters,and strategies to manage guide and cope, and internal/ external testing strategies. Thesework in guaranteeing quality and performance, and as such, establishing "Digital Platformfor Integrated Research of Coronavirus disease 2019 (COVID-19)".

Coronavirus disease 2019 (COVID-19) is an infectious disease. Physical distancing is oneof the most effective ways to reduce the spread of COVID-19, but this key preventionintervention may have adverse consequences on older adults living at home. Screeningolder adults living at home and at risk for adverse consequences of physical and socialdistancing is, therefore, a priority in order to prevent their occurrence. ESOGER("Evaluation Social et GERiatrique") is a clinical tool designed to: 1) screen therisk-levels for adverse consequences related to COVID-19 physical distancing and 2) tocontinue appropriate preventive interventions in older adults living at home includingfrail older patients and older community dwellers. Experience cumulated during the pasttwo weeks revealed that ESOGER could be improved, in order to be more effective andefficient for the prevention of adverse consequences related to COVID-19 physicaldistancing. This improvement is based on two key components: 1) Comments of MontrealESOGER users and 2) Analysis of data. Because at this time no information is saved andstored, there is a need to save and store ESOGER information and create the ESOGERdatabank.